The United Kingdom is now discovering the steep price of exclusion. By leaving its powerful pharmaceutical industry out of a tariff agreement with the United States five months ago, the country has incurred a massive political and economic debt that is now coming due in the form of a threatened 100% duty on branded drugs.
This crisis is a direct and foreseeable consequence of that initial decision. The deal, negotiated by Keir Starmer, created a two-tier system of protection for British industry. It threw a lifeline to car and steel manufacturers while leaving drugmakers to fend for themselves. The Trump administration has now identified this unprotected flank and is exploiting it with surgical precision.
The price of this exclusion is being paid in multiple currencies. There is the immediate economic cost, with a vital industry facing potential devastation. There is the political cost, as the current government is forced to clean up a mess inherited from a previous negotiation, making it appear weak and reactive on the world stage.
There is also the strategic cost. The episode has damaged the UK’s reputation for competent trade negotiation and has sown deep anxiety within one of its most successful and innovative sectors. The government’s promise to “actively engage” with Washington is an attempt to stanch the bleeding, but the wound was self-inflicted through the original act of exclusion.
As the UK scrambles to find a solution, the lesson is painfully clear. In the high-stakes world of international trade, partial victories can quickly turn into major defeats. By failing to secure a comprehensive agreement that protected all of its key assets, the UK left a critical industry exposed and is now being forced to pay the heavy price.